ERO1A and hepatocellular carcinoma: Interestingly, overexpression of ERO1α tends to have a worse prognosis in multiple cancer indications; multiple myeloma [36], breast [37–39] and hepatocellular carcinoma [40], as well as lung, esophageal, diffuse B-cell lymphoma, and others according to The Cancer Genome Atlas (TCGA) and The Protein Atlas.